Drugs / GMCN-508A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05757245 | May 2023 → Aug 2028 expected | alpha thalassemia spectrum | First Affiliated Hospital of Guangxi Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMCN-508A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05757245 ↗ |
| Known as | GMCN-508A Drug Product | “This is a non-randomized, open label, single-site, single-dose, phase 1 study in up to 5 participants (between 5 and 35 years of age, inclusive) with Transfusion-dependent...” NCT05757245 ↗ |